演講研討會公告
Siglec-8 and Siglec-F on allergic effector cells: cell biology, glycan ligands and functions learned from preclinical and clinical targeting
2019-11-18 11:00 ~ 2019-11-18 12:00
地點: 生化所209室
主講人: Dr. Bruce S. Bochner
主講人背景: 美國西北大學醫學院教授
主講人網站: https://www.feinberg.northwestern.edu/faculty-profiles/az/profile.html?xid=28140
演講主持人: 安形高志副研究員
演講摘要:
Eosinophils and mast cells play important roles in type 2 immunity, inflammation and other responses. Sialic acid-binding, immunoglobulin-like lectins (Siglecs) are single-pass transmembrane cell surface receptors found primarily on subsets of leukocytes. Over the past 20 years, our knowledge of the expression and function of Siglecs on cells of the immune system and others has greatly expanded, as has our understanding of their signaling, ligands, and possible roles in disease pathophysiology. Most Siglecs, but not all, have conserved cytoplasmic signalling motifs that suggest they primarily function as inhibitory receptors. Among these, Siglec-8, first discovered in 2000, is selectively expressed on human eosinophils and mast cells. Its closest murine counterpart is Siglec-F, although there are several very important functional and phenotypic differences between mouse Siglec-F and human Siglec-8. It is now known that Siglec-8 engagement, either by specific antibodies or via multivalent, specific α2,3-linked sialylated, sulphated artificial or endogenous glycan ligands, can result in a number of responses in vitro including reduced eosinophil survival and altered integrin function, as well as reduced mast cell secretion responses. Its unique glycan ligand specificity has facilitated the discovery of some endogenous airway ligands for both Siglec-F and Siglec-8 and their mechanisms of synthesis. Because Siglec-8 is only expressed on human and primate cells, novel knock-in strains of mice have been developed in which Siglec-8 gets selectively expressed on eosinophils, mast cells, or both cell types, enabling further preclinical studies of its functional role in vivo. Finally, a biotechnology company called Allakos, Inc. has created a humanized non-fucosylated IgG1 monoclonal antibody named antolimab (formerly called AK002) that is being tested in clinical trials for the treatment of various diseases involving eosinophils and/or mast cells.-Dr. Bruce S. Bochner
洽詢人員: 劉小姐
洽詢電話: 02-27855696#2061
洽詢信箱: liukchun@gate.sinica.edu.tw